Crinetics Pharmaceuticals Inc

CRNX is in a Stage 2 advancing phase within a secular uptrend, marked by a parabolic breakout above rising EMAs that confirms medium-term bullish bias; however, price is extreme overbought and extended, and speculative strategy prioritizes patient pullback entries into the 9/21 EMA support zone.

• ↑$1.3B cash balance supports operations through 2030
• ↑232 new patient enrollments in Q1 indicate strong uptake
• ↓Q1 R&D spend $100.1M (+17.7% YoY) pressuring margins